A new, comprehensive analysis from KFF (formerly the Kaiser Family Foundation) has cast a bright light on the opaque world of prior authorization, revealing startling inconsistencies in how health insurance companies manage patient access to care. By scrutinizing newly released federal data, the non-profit health policy organization has confirmed what clinicians have long suspected: whether a patient receives timely approval for a procedure often depends less on clinical necessity and more on which insurance plan they happen to hold.
The findings, which cover the 2025 landscape for Medicare Advantage (MA), Medicaid Managed Care Organizations (MCOs), and Affordable Care Act (ACA) marketplaces, indicate that denial rates are not only high but wildly variable. This analysis arrives at a critical juncture in U.S. healthcare, as both the federal government and state legislatures face mounting pressure to rein in utilization management practices that critics argue jeopardize patient outcomes.
The Landscape of Prior Authorization
Prior authorization—the process by which healthcare providers must obtain pre-approval from an insurance company before performing a service or prescribing a drug—is ostensibly designed to curb unnecessary spending and ensure care adheres to evidence-based guidelines. However, the reality on the ground, according to the American Medical Association and other provider groups, is a labyrinthine administrative burden that frequently delays life-saving treatments and contributes to physician burnout.
The KFF analysis examined 14 of the largest insurers across each of the three major market segments. The results quantify a reality that has historically been obscured by a lack of public reporting. Across the board, insurers denied an average of 12% of standard requests in Medicare Advantage, 14% in Medicaid MCOs, and a staggering 18% in ACA marketplaces. While expedited requests—those flagged as urgent—tended to have lower denial rates, the systemic nature of these rejections underscores the friction inherent in modern insurance coverage.
Chronology: The Regulatory Push for Transparency
The current push for transparency is not an overnight development. It is the culmination of years of legislative advocacy and regulatory evolution.
- 2019: The Centers for Medicare & Medicaid Services (CMS) first implemented requirements for Medicare Advantage plans to report limited data on prior authorization metrics. This served as a pilot for broader oversight.
- 2024: Recognizing the systemic nature of the issue, CMS issued a landmark final rule aimed at streamlining and digitizing the prior authorization process. This rule mandated that insurers improve their turnaround times and, crucially, expanded reporting requirements to include Medicaid MCOs and ACA marketplace plans for the first time.
- Summer 2024: Facing political pressure from the Trump administration’s healthcare reform agenda, major insurers pledged to pare back their most onerous prior authorization policies. These voluntary commitments aimed to curb the volume of requests, with the industry claiming an 11% reduction in requirements by April of this year.
- 2025: The first full cycle of the new, broadened reporting requirements provides the foundation for the KFF report, offering the most granular look at payer behavior to date.
Supporting Data: A Market Divided
The KFF report highlights a profound lack of uniformity in how insurance companies interpret clinical necessity. The range of denial rates within each sector suggests that internal company policies, rather than patient health needs, are the primary drivers of authorization outcomes.
Medicare Advantage (MA)
In the MA sector, the disparity is stark. While some insurers maintain relatively lean approval processes, others are significantly more restrictive. The data shows denial rates ranging from as low as 5% for insurers like Elevance to as high as 17% for UnitedHealth. This 12-percentage-point gap indicates that a senior citizen’s access to care is statistically dependent on their choice of private plan.
Medicaid Managed Care
The Medicaid landscape, which serves the nation’s most vulnerable populations, exhibits even wider variance. The analysis found that L.A. Care Plan reported a minimal 2% denial rate, whereas Independent Health Group reached a high of 23%. This discrepancy raises significant equity concerns, particularly for low-income patients who may lack the resources to navigate complex appeals processes.
ACA Marketplaces
The ACA segment saw the most extreme volatility, with denial rates ranging from 3% (Guidewell) to 25% (Centene). With one in four requests being denied at the top end of the spectrum, the barrier to access for marketplace consumers is substantially higher than in other insurance sectors, potentially discouraging enrollment or leading to deferred care.
The "Appeal" Gap: Success vs. Utilization
Perhaps the most troubling finding in the KFF analysis relates to the success of appeals. When a request is denied, it is not necessarily because the care is medically inappropriate; rather, it is often a result of incomplete documentation or overly stringent automated criteria.
KFF found that when patients or providers do fight back, they often win. In Medicare Advantage, two-thirds of appealed claims were ultimately approved. In Medicaid, half of denials were overturned, and in the ACA marketplaces, 43% of denied claims were eventually authorized upon appeal.
This data exposes a "success gap." Because the appeals process is notoriously difficult, time-consuming, and confusing, very few patients actually challenge a denial. The high reversal rate suggests that a significant portion of initial denials are "false negatives"—cases where the patient was entitled to care but was initially told they were not.
Implications for the Healthcare System
The implications of these findings are profound, affecting every stakeholder in the healthcare ecosystem.
For Patients
The primary victim of the current prior authorization regime is the patient. Delayed care can lead to disease progression, chronic pain, and increased psychological distress. The "appeal gap" means that only those with the time, resources, and clinical support are able to secure the care they are entitled to, deepening existing health disparities.
For Providers
Clinicians are reaching a breaking point. The administrative cost of managing prior authorizations—including staffing dedicated personnel to handle phone calls, faxes, and portal submissions—is a major contributor to the rising cost of medical practice. Many physicians argue that the burden is driving them out of private practice and toward hospital-employed models, reducing competition and increasing costs.
For Insurers and Regulators
The KFF analysis serves as a warning that voluntary industry commitments may not be enough. While insurers have claimed to cut 11% of their prior authorization requirements, the 2025 data suggests that the remaining mechanisms are still being applied with high frequency and extreme variability.
There are also significant structural challenges to overcome. KFF noted that the current data is limited by several factors:
- Lack of Volume Data: Insurers report percentages, but not the raw number of requests. Without knowing the total volume, it is difficult to determine if a low denial percentage represents a "fair" insurer or one that simply processes fewer requests.
- Inconsistent Reporting: Because there is no standardized format for these reports, comparing one insurer to another is akin to comparing apples and oranges.
- Lack of Granularity: The data does not break down denials by service type. We cannot see if insurers are disproportionately targeting expensive surgeries, diagnostic imaging, or prescription medications.
Future Outlook: The Path Toward Reform
As the federal government continues to implement its 2024 final rule, the next steps for policymakers are clear. There is an urgent need for standardization in reporting. To truly protect consumers, CMS must mandate that insurers provide the total number of requests, the types of services being targeted, and clear, standardized definitions for what constitutes a "denial."
Furthermore, there is growing bipartisan support for "gold-carding" programs—a policy that would exempt physicians with high historical approval rates from the prior authorization process entirely. By rewarding providers who consistently adhere to evidence-based care, the industry could reduce the administrative burden on both doctors and insurers, focusing oversight efforts on true outliers.
Ultimately, the KFF data confirms that prior authorization has evolved into a high-stakes, high-variability game of chance for patients. The era of "black box" utilization management is coming to an end, but the transition to a more transparent, patient-centered system will require more than just reporting—it will require a fundamental shift in how the healthcare industry balances fiscal responsibility with its primary mandate: the delivery of timely, necessary care.
